Menu

Biology, Genetics & Bone Healing MCQs

Practice Set 106 of 212

This practice set contains high-yield board review questions covering key concepts in Biology, Genetics & Bone Healing. Each clinical scenario is designed to test your diagnostic and management skills relevant to this subspecialty.

Question 2101

Topic: Biology, Genetics & Bone Healing

A 6-year-old girl with blue sclerae, dentinogenesis imperfecta, and a history of multiple low-energy long bone fractures is diagnosed with Osteogenesis Imperfecta (OI). She is started on an intravenous bisphosphonate protocol. What is the primary cellular mechanism of action of this medication in the treatment of her condition?

. Stimulation of osteoblast proliferation and differentiation
. Inhibition of osteoclast-mediated bone resorption by inducing apoptosis
. Direct enhancement of Type I collagen structural cross-linking
. Augmentation of intestinal calcium and phosphate absorption
. Inhibition of parathyroid hormone secretion from the parathyroid glands

Correct Answer & Explanation

. Inhibition of osteoclast-mediated bone resorption by inducing apoptosis

Explanation

Bisphosphonates are taken up by osteoclasts during bone resorption, leading to inhibition of the mevalonate pathway, loss of osteoclast function, and subsequent apoptosis. This decreases the overall rate of bone turnover, increasing bone mineral density in OI patients.

Question 2102

Topic: Biology, Genetics & Bone Healing

A 9-year-old boy is evaluated for unusual shoulder mobility. On examination, he is able to approximate his shoulders in the midline anteriorly. Physical exam also reveals a broad skull, delayed fontanelle closure, and multiple retained deciduous teeth. A mutation in which of the following genes is responsible for this patient's condition?

. COL1A1
. FGFR3
. RUNX2 (CBFA1)
. COMP
. SOX9

Correct Answer & Explanation

. RUNX2 (CBFA1)

Explanation

The patient has Cleidocranial Dysplasia, characterized by hypoplastic/aplastic clavicles, delayed skull ossification, and dental anomalies. It is caused by an autosomal dominant mutation in the RUNX2 (also known as CBFA1) gene, which is essential for osteoblast differentiation.

Question 2103

Topic: Biology, Genetics & Bone Healing

A 5-year-old girl is diagnosed with oligoarticular Juvenile Idiopathic Arthritis primarily affecting her right knee. She has an antinuclear antibody (ANA) positive titer. In addition to monitoring for leg length discrepancies, what mandatory screening must be instituted?

. Annual echocardiography
. Quarterly slit-lamp examinations
. Monthly liver function tests
. Biannual hearing tests
. Yearly DEXA scans

Correct Answer & Explanation

. Quarterly slit-lamp examinations

Explanation

Children with ANA-positive oligoarticular JIA are at a high risk for developing asymptomatic chronic anterior uveitis. Frequent screening with a slit-lamp examination by an ophthalmologist is critical to prevent permanent vision loss.

Question 2104

Topic: Biology, Genetics & Bone Healing

A 22-year-old female presents with a destructive, eccentric, lytic lesion in the distal radius subchondral bone. Histology shows sheets of mononuclear cells with numerous multinucleated giant cells. Which targeted pharmacological therapy is indicated if the tumor is deemed unresectable or for massive recurrence?

. Imatinib
. Denosumab
. Methotrexate
. Doxorubicin
. Zoledronic acid

Correct Answer & Explanation

. Denosumab

Explanation

The patient has a Giant Cell Tumor (GCT) of bone. Denosumab, a monoclonal antibody against RANKL, inhibits osteoclast-like giant cell formation and is effectively used to downstage unresectable or recurrent GCTs.

Question 2105

Topic: Biology, Genetics & Bone Healing

A 32-year-old female presents with a purely lytic, eccentric lesion in the epiphysis extending into the metaphysis of the distal femur. A biopsy reveals numerous multinucleated giant cells in a stroma of mononuclear cells. If medical therapy is considered, which drug specifically targets the primary molecular pathway driving this tumor?

. Bisphosphonates
. Denosumab
. Imatinib
. Methotrexate
. Doxorubicin

Correct Answer & Explanation

. Denosumab

Explanation

The diagnosis is Giant Cell Tumor of bone. The neoplastic mononuclear stromal cells express RANKL, which recruits and activates the multinucleated osteoclast-like giant cells; Denosumab is a monoclonal antibody that binds and inhibits RANKL.

Question 2106

Topic: Biology, Genetics & Bone Healing

A 65-year-old male presents with widespread lytic bone lesions, renal insufficiency, and hypercalcemia. A diagnosis of Multiple Myeloma is established. Which of the following best describes the molecular mechanism responsible for the osteolytic bone lesions in this disease?

. Tumor cells directly resorb bone via secretion of matrix metalloproteinases
. Myeloma cells secrete MIP-1 alpha and RANKL, intensely stimulating osteoclast activity
. Myeloma cells produce large amounts of osteoprotegerin (OPG), blocking bone formation
. Tumor cells secrete high levels of Parathyroid Hormone (PTH)
. Tumor cells secrete Fibroblast Growth Factor 23 (FGF-23) causing phosphate wasting

Correct Answer & Explanation

. Myeloma cells secrete MIP-1 alpha and RANKL, intensely stimulating osteoclast activity

Explanation

In Multiple Myeloma, malignant plasma cells secrete cytokines such as MIP-1 alpha and upregulate RANKL. This creates a highly osteoclastogenic microenvironment, leading to unchecked bone resorption and lytic lesions.

Question 2107

Topic: Biology, Genetics & Bone Healing

Giant Cell Tumor (GCT) of bone frequently causes significant local bone destruction. The osteolysis in GCT is driven by the interaction between RANKL and RANK. In this tumor, which cells express RANKL?

. The reactive multinucleated giant cells
. The mononuclear neoplastic stromal cells
. The circulating T-lymphocytes
. The adjacent reactive osteoblasts
. The endothelial cells of the tumor vasculature

Correct Answer & Explanation

. The mononuclear neoplastic stromal cells

Explanation

In Giant Cell Tumor of bone, the mononuclear stromal cells are the true neoplastic components and they heavily express RANKL. This cytokine recruits and activates normal, reactive multinucleated osteoclast-like giant cells that cause the bone destruction.

Question 2108

Topic: Biology, Genetics & Bone Healing

A patient undergoes distraction osteogenesis using an Ilizarov frame. Six weeks post-operatively, radiographs show a lucent zone in the regenerate without evidence of bridging callus. The distraction rate is 1.0 mm per day. What is the most appropriate management for this delayed consolidation?

. Increase the rate of distraction to 1.5 mm per day.
. Remove the external fixator and apply a walking cast.
. Perform an accordion maneuver (alternating compression and distraction).
. Perform a second corticotomy at a different level.
. Administer systemic bisphosphonates immediately.

Correct Answer & Explanation

. Perform an accordion maneuver (alternating compression and distraction).

Explanation

Delayed consolidation or poor regenerate during distraction osteogenesis can be stimulated by the "accordion maneuver," which involves sequential cycles of compression and distraction to stimulate osteogenesis at the regenerate site.

Question 2109

Topic: Biology, Genetics & Bone Healing

A 6-year-old child with NF1 presents with established anterolateral bowing and non-union of the tibia.

What is the primary histological finding at the site of the pseudoarthrosis that impairs healing?

. Avascular necrosis of the bone ends
. Thickened, fibrous hamartomatous periosteum
. Malignant transformation of osteoblasts
. Accumulation of woven bone without osteoclasts
. Infiltration of malignant peripheral nerve sheath tumor

Correct Answer & Explanation

. Thickened, fibrous hamartomatous periosteum

Explanation

In congenital anterolateral bowing of the tibia associated with NF1, the pseudoarthrosis site is enveloped by a thickened, fibrous, hamartomatous periosteum. This abnormal tissue acts as a mechanical and biological barrier, severely impairing local vascularization and bone union.

Question 2110

Topic: Biology, Genetics & Bone Healing

What is the primary function of the protein mutated in Neurofibromatosis type 1?

. Tyrosine kinase activation
. Wnt pathway inhibition
. Downregulation of the Ras pathway via GTPase activation
. RANKL inhibition
. Bone morphogenetic protein receptor signaling

Correct Answer & Explanation

. Downregulation of the Ras pathway via GTPase activation

Explanation

NF1 is caused by a mutation in the NF1 gene on chromosome 17q11.2, which encodes neurofibromin. Neurofibromin acts as a tumor suppressor by downregulating the Ras signaling pathway via its GTPase-activating protein (GAP) activity.

Question 2111

Topic: Biology, Genetics & Bone Healing

A 30-year-old female presents with an expansile, lytic lesion in the distal femur extending to the subchondral bone. Biopsy confirms a Giant Cell Tumor. What is the mechanism of action of Denosumab, a frequently used neoadjuvant therapy?

. Inhibits vascular endothelial growth factor (VEGF)
. Binds to RANKL, preventing osteoclast activation
. Direct cytotoxic effect on mononuclear neoplastic cells
. Tyrosine kinase inhibition
. Stimulates osteoblast bone formation

Correct Answer & Explanation

. Binds to RANKL, preventing osteoclast activation

Explanation

Denosumab is a monoclonal antibody that binds to RANKL, preventing it from interacting with the RANK receptor on osteoclasts. This inhibits osteoclast-mediated bone destruction, which is driven by the neoplastic mononuclear cells in GCT.

Question 2112

Topic: Biology, Genetics & Bone Healing

The gene mutated in Neurofibromatosis Type 1 (NF1) encodes for the protein neurofibromin. What is the normal cellular function of this protein?

. It acts as a GTPase-activating protein (GAP) that downregulates the Ras signaling pathway.
. It functions as a tyrosine kinase receptor promoting osteoblast differentiation.
. It acts as a tumor suppressor by directly binding to the p53 promoter region.
. It cross-links actin filaments to the cell membrane, stabilizing Schwann cells.
. It upregulates the Wnt/beta-catenin pathway to stimulate endochondral ossification.

Correct Answer & Explanation

. It acts as a GTPase-activating protein (GAP) that downregulates the Ras signaling pathway.

Explanation

Neurofibromin functions as a GTPase-activating protein (GAP) that normally inhibits the Ras signaling pathway. Loss of neurofibromin leads to constitutively active Ras, driving uncontrolled cell proliferation and tumor formation in NF1 patients.

Question 2113

Topic: Biology, Genetics & Bone Healing

A 15-year-old boy presents with knee pain. Radiographs reveal an eccentric, lytic lesion in the distal femoral epiphysis extending to the subchondral bone. Biopsy confirms a Giant Cell Tumor (GCT). Which cellular component is the true neoplastic cell, and which signaling molecule does it express to drive osteolysis?

. Multinucleated giant cells; expressing RANKL.
. Multinucleated giant cells; expressing Osteoprotegerin (OPG).
. Mononuclear stromal cells; expressing RANKL.
. Mononuclear stromal cells; expressing RANK.
. Osteoblasts; expressing Sclerostin.

Correct Answer & Explanation

. Mononuclear stromal cells; expressing RANKL.

Explanation

In GCT of bone, the spindle-shaped mononuclear stromal cells are the true neoplastic elements. They overexpress RANKL, which recruits and activates normal host macrophages to fuse into the osteolytic multinucleated giant cells.

Question 2114

Topic: Biology, Genetics & Bone Healing

A 5-year-old boy is diagnosed with Neurofibromatosis type 1 (NF-1). Which of the following best describes the molecular pathophysiology of his condition?

. Decreased inhibition of the Ras-MAPK pathway
. Gain-of-function mutation in the FGFR3 gene
. Defect in type 1 collagen synthesis
. Overexpression of the RANKL protein
. Mutation in the RUNX2 transcription factor

Correct Answer & Explanation

. Decreased inhibition of the Ras-MAPK pathway

Explanation

NF-1 is caused by a mutation in the NF1 gene on chromosome 17, which encodes the tumor suppressor neurofibromin. Neurofibromin normally downregulates the Ras-MAPK pathway; its loss leads to uncontrolled cell proliferation and tumor formation.

Question 2115

Topic: Biology, Genetics & Bone Healing

A 28-year-old woman presents with knee pain. Radiographs show an eccentric, expansile, lytic lesion in the distal femur extending to the subchondral bone without a sclerotic margin. Biopsy shows multinucleated giant cells in a background of mononuclear stromal cells. If systemic medical therapy is indicated, which molecular pathway is the primary target?

. Vascular endothelial growth factor (VEGF) pathway
. RANK ligand (RANKL) pathway
. Fibroblast growth factor receptor 3 (FGFR3) pathway
. Wnt/beta-catenin signaling pathway
. PD-1 immune checkpoint pathway

Correct Answer & Explanation

. RANK ligand (RANKL) pathway

Explanation

Giant cell tumors of bone are driven by neoplastic mononuclear stromal cells that overexpress RANKL, which aggressively recruits and activates osteoclast-like multinucleated giant cells. Denosumab, a monoclonal antibody against RANKL, blocks this pathway and is used for advanced or inoperable cases.

Question 2116

Topic: Biology, Genetics & Bone Healing

A 28-year-old female presents with knee pain. Radiographs show an eccentric, lytic epiphyseal lesion in the proximal tibia. Biopsy confirms Giant Cell Tumor (GCT). If medical management is considered prior to curettage to downstage the tumor, what is the mechanism of action of the preferred agent?

. Inhibits osteoclast activity via direct bisphosphonate binding
. Monoclonal antibody that binds and inhibits RANKL
. Tyrosine kinase inhibitor targeting VEGF
. Selective estrogen receptor modulator reducing osteoclastogenesis
. Cross-links DNA to inhibit tumor replication directly

Correct Answer & Explanation

. Monoclonal antibody that binds and inhibits RANKL

Explanation

Denosumab is a monoclonal antibody that binds to RANKL, inhibiting osteoclast differentiation and function. It is frequently used in challenging GCT cases to ossify the tumor periphery and facilitate a more complete curettage.

Question 2117

Topic: Biology, Genetics & Bone Healing

A 32-year-old female presents with a destructive, expansile, purely lytic lesion in the distal femur epiphysis. Biopsy confirms a Giant Cell Tumor (GCT) of bone. She is treated preoperatively with denosumab. What is the primary mechanism of action of this medication in the context of GCT?

. Directly induces apoptosis of the neoplastic mononuclear stromal cells
. Inhibits RANK ligand (RANKL), preventing the recruitment and activation of reactive osteoclast-like giant cells
. Blocks vascular endothelial growth factor (VEGF) to decrease tumor vascularity
. Inhibits the mTOR pathway, leading to tumor necrosis
. Binds to the extracellular matrix to inhibit tumor invasion

Correct Answer & Explanation

. Inhibits RANK ligand (RANKL), preventing the recruitment and activation of reactive osteoclast-like giant cells

Explanation

Denosumab is a monoclonal antibody that binds to RANKL, which is overexpressed by the neoplastic mononuclear stromal cells in GCT. This prevents RANKL from binding to RANK on osteoclast precursors, thereby halting the formation of bone-resorbing giant cells.

Question 2118

Topic: Biology, Genetics & Bone Healing

Regarding Glucocorticoid-Induced Osteoporosis (GIO) in orthopedic patients undergoing chronic steroid therapy, which mechanism primarily drives the rapid early bone loss?

. Increased intestinal calcium absorption
. Decreased renal calcium excretion
. Increased osteoblast apoptosis and reduced osteoblastogenesis
. Overproduction of parathyroid hormone (PTH)
. Increased calcitonin secretion

Correct Answer & Explanation

. Increased osteoblast apoptosis and reduced osteoblastogenesis

Explanation

GIO primarily results from direct inhibitory effects on bone formation. Glucocorticoids increase the apoptosis of mature osteoblasts and osteocytes while simultaneously decreasing new osteoblastogenesis.

Question 2119

Topic: Biology, Genetics & Bone Healing
A 5-year-old boy presents with six café-au-lait spots and axillary freckling. He is diagnosed with Neurofibromatosis Type 1 (NF1). The mutated gene in this condition normally functions to downregulate which of the following signaling pathways?
. Wnt/beta-catenin
. Hedgehog
. Ras-MAPK
. PI3K/AKT
. TGF-beta

Correct Answer & Explanation

. Ras-MAPK

Explanation

NF1 is caused by an autosomal dominant mutation in the NF1 gene on chromosome 17. This gene encodes neurofibromin, a GTPase-activating protein that normally downregulates the Ras-MAPK pathway to prevent uncontrolled cellular proliferation.

Question 2120

Topic: Biology, Genetics & Bone Healing

A 32-year-old female presents with a large, lytic epiphyseal lesion of the distal femur. Biopsy confirms Giant Cell Tumor of bone (GCT). If medical therapy with denosumab is considered prior to surgery, which cellular interaction is primarily targeted?

. Inhibition of RANKL produced by the multinucleated giant cells
. Inhibition of RANKL produced by the neoplastic mononuclear stromal cells
. Direct apoptosis of the neoplastic mononuclear stromal cells
. Activation of osteoprotegerin (OPG) by the multinucleated giant cells
. Inhibition of RANK receptor on the neoplastic mononuclear stromal cells

Correct Answer & Explanation

. Inhibition of RANKL produced by the neoplastic mononuclear stromal cells

Explanation

In GCT, the true neoplastic cells are the mononuclear stromal cells, which overexpress RANKL. Denosumab binds to this RANKL, preventing it from activating the RANK receptor on the reactive, bone-resorbing multinucleated giant cells.

Test Yourself

Switch to an interactive, timed exam simulation to truly master this topic.

On this Page